Correlation of treatment time and ultrafiltration rate with serum albumin and C-reactive protein levels in patients with end-stage kidney disease receiving chronic maintenance hemodialysis: A cross-sectional study

Blood Purification

Volumn 30, Issue 1, 2010, Pages 8-15

  Zsom, Lajos ^a   Zsom, Marianna ^b   Fülöp, Tibor ^a   Wells, Catherine ^a   Flessner, Michael F ^a   Eller, József ^c   Wollheim, Charlotta ^d   Hegbrant, Jörgen ^d   Strippoli, Giovanni F M ^d,e  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b Diaverum Dialysis Center   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d Diaverum Medical Scientific Office   (Sweden)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

C reactive protein; Hemodialysis treatment time; Serum albumin; Ultrafiltration rate

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CALCIMIMETIC AGENT; CALCITRIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHATE BINDING AGENT; SERUM ALBUMIN; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; CONGESTIVE HEART FAILURE; FEMALE; HEMODIALYSIS; HUMAN; INFECTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; ULTRAFILTRATION;

C-REACTIVE PROTEIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEMODIAFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SERUM ALBUMIN; TIME FACTORS;

EID: 77952306012     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314648     Document Type: Article

References (50)

1. McDonald SP, Craig JC, Australian and New Zealand Paediatric Nephrology Association: Long-term survival of children with endstage renal disease. N Engl J Med 2004; 350: 2654-2662.
2. Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, Bloembergen WE, Greer JW, Hakim RM: The dose of hemodialysis and patient mortality. Kidney Int 1996; 50: 550-556.
3. Hakim RM, Breyer J, Ismail N, Schulman G: Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23: 661-669.
4. Sargent JA, Gotch FA: The analysis of concentration dependence of uremic lesions in clinical studies. Kidney Int Suppl 1975: 35-44.
5. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
6. Paniagua R, Amato D, Vonesh E, Correa- Rotter R, Ramos A, Moran J, Mujais S, Mexican Nephrology Collaborative Study Group: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320.
7. Johnson WJ, Hagge WW, Wagoner RD, Dinapoli RP, Rosevear JW: Effects of urea loading in patients with far-advanced renal failure. Mayo Clin Proc 1972; 47: 21-29.
8. Zsom L, Zsom M, Fulop T, Flessner MF: Treatment time, chronic inflammation, and hemodynamic stability: the overlooked parameters in hemodialysis quantification. Semin Dial 2008; 21: 395-400.
9. McCusker FX, Teehan BP, Thorpe KE, Keshaviah PR, Churchill DN: How much peritoneal dialysis is required for the maintenance of a good nutritional state? Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Kidney Int Suppl 1996; 56:S56-S61.
10. Bargman JM, Thorpe KE, Churchill DN, CANUSA Peritoneal Dialysis Study Group: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162.
11. Iseki K, Kawazoe N, Fukiyama K: Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 1993; 44: 115-119.
12. Fung F, Sherrard DJ, Gillen DL, Wong C, Kestenbaum B, Seliger S, Ball A, Stehman- Breen C: Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis 2002; 40: 307-314. (Pubitemid 34827648)
13. Cooper BA, Penne EL, Bartlett LH, Pollock CA: Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. Am J Kidney Dis 2004; 43: 61-66.
14. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482.
15. Beddhu S, Cheung AK, Larive B, Greene T, Kaysen GA, Levey AS, Rocco M, Sarnak M, Toto R, Eknoyan G, Hemodialysis (HEMO) Study Group: Inflammation and inverse associations of body mass index and serum creatinine with mortality in hemodialysis patients. J Ren Nutr 2007; 17: 372-380.
16. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476.
17. Apple FS, Murakami MM, Pearce LA, Herzog CA: Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004; 50: 2279-2285.
18. Black S, Kushner I, Samols D: C-reactive protein. J Biol Chem 2004; 279: 48487-48490.
19. Lee CT, Lee CH, Su Y, Chuang YC, Tsai TL, Cheni JB: The relationship between inflammatory markers, leptin and adiponectin in chronic hemodialysis patients. Int J Artif Organs 2004; 27: 835-841.
20. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114.
21. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B: Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148.
22. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergström J: Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 1998; 53: 773-782.
23. Kaysen GA, Chertow GM, Adhikarla R, Young B, Ronco C, Levin NW: Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001; 60: 333-340.
24. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, McAllister CJ, Alcorn H Jr, Kopple JD, Greenland S: Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant 2005; 20: 1880-1888.
25. Kaysen GA, Rathore V, Shearer GC, Depner TA: Mechanisms of hypoalbuminemia in hemodialysis patients. Kidney Int 1995; 48: 510-516.
26. Kaysen GA, Don BR: Factors that affect albumin concentration in dialysis patients and their relationship to vascular disease. Kidney Int Suppl 2003:S94-S97.
27. Kalantar-Zadeh K: Inflammatory marker mania in chronic kidney disease: pentraxins at the crossroad of universal soldiers of inflammation. Clin J Am Soc Nephrol 2007; 2: 872-875.
28. Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK: Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69: 1222-1228.
29. Bean BK, Lam SG, Schmidt DW, Zsom L, Wells CH: Comparison in clinical outcomes and a European Hemodialysis Unit (abstract). J Am Soc Nephrol 2008; 19: 507A.
30. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M: IL-10, IL- 6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233.
31. Caglar K, Peng Y, Pupim LB, Flakoll PJ, Levenhagen D, Hakim RM, Ikizler TA: Inflammatory signals associated with hemodialysis. Kidney Int 2002; 62: 1408-1416.
32. Kaysen GA, Rathore V, Shearer GC, Depner TA: Mechanisms of hypoalbuminemia in hemodialysis patients. Kidney Int 1995; 48: 510-516.
33. Zhou YL, Liu HL, Duan XF, Yao Y, Sun Y, Liu Q: Impact of sodium and ultrafiltration profiling on haemodialysis-related hypotension. Nephrol Dial Transplant 2006; 21: 3231-3237.
34. Selby NM, McIntyre CW: The acute cardiac effects of dialysis. Semin Dial 2007; 20: 220-228.
35. Shoji T, Tsubakihara Y, Fujii M, Imai E: Hemodialysis- associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004; 66: 1212-1220.
36. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT, NECOSAD Study Group: Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004; 15: 1061-1070.
37. Boxall MC, Goodship TH, Brown AL, Ward MC, von Zglinicki T: Telomere shortening and haemodialysis. Blood Purif 2006; 24: 185-189.
38. Dhondt A, Vanholder R, Van Biesen W, Lameire N: The removal of uremic toxins. Kidney Int Suppl 2000; 76:S47-S59.
39. Chazot C, Vo-VAN C, Blanc C, Hurot JM, Jean G, Vanel T, Terrat JC, Charra B: Stability of nutritional parameters during a 5-year follow-up in patients treated with sequential long-hour hemodialysis. Hemodial Int 2006; 10: 389-393.
40. Stenvinkel P, Lindholm B: C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif 2005; 23: 72-78.
41. Furuya R, Kumagai H, Takahashi M, Sano K, Hishida A: Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients. Blood Purif 2005; 23: 311-316.
42. Honda H, Suzuki H, Hosaka N, Hirai Y, Sanada D, Nakamura M, Nagai H, Ashikaga E, Matsumoto K, Mukai M, Watanabe M, Akizawa T: Ultrapure dialysate influences serum myeloperoxidase levels and lipid metabolism. Blood Purif 2009; 28: 29-39.
43. Windram JD, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JG: Relationship of highsensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J 2007; 153: 1048-1055.
44. Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, Szklo M, Lima JA: Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008; 51: 1775-1783.
45. Ortega O, Gallar P, Muñoz M, Rodríguez I, Carreño A, Ortiz M, Molina A, Oliet A, Lozano L, Vigil A: Association between C-reactive protein levels and N-terminal pro- B-type natriuretic peptide in pre-dialysis patients. Nephron Clin Pract 2004; 97:c125-c130.
46. Avila-Díaz M, Ventura MD, Valle D, Vicenté-Martínez M, García-González Z, Cisneros A, Furlong MD, Gómez AM, Prado- Uribe MD, Amato D, Paniagua R: Inflammation and extracellular volume expansion are related to sodium and water removal in patients on peritoneal dialysis. Perit Dial Int 2006; 26: 574-580.
47. Fulop T, Rule AD, Schmidt DW, Wiste HJ, Bailey KR, Kullo IJ, Schwartz GL, Mosley TH, Boerwinkle E, Turner ST: C-reactive protein among community-dwelling hypertensives on single-agent antihypertensive treatment. J Am Soc Hypertens 2009; 3: 260-266.
48. Panichi V, Migliori M, De Pietro S, Metelli MR, Taccola D, Perez R, Palla R, Rindi P, Cristofani R, Tetta C: Plasma C-reactive protein in hemodialysis patients: a cross-sectional, longitudinal clinical survey. Blood Purif 2000; 18: 30-36.
49. Kadiroglu AK, Kadiroglu ET, Sit D, Dag A, Yilmaz ME: Periodontitis is an important and occult source of inflammation in hemodialysis patients. Blood Purif 2006; 24: 400-404.
50. Marshall MR, Byrne BG, Kerr PG, McDonald SP: Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int 2006; 69: 1229-1236.